Pages that link to "Q73078396"

The following pages link to Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models (Q73078396):

Displaying 33 items.

• Epithelial Membrane Protein-2 Promotes Endometrial Tumor Formation through Activation of FAK and Src (Q24305365) (← links)
• Progress of molecular targeted therapies for prostate cancers (Q26823014) (← links)
• Prostate cancer relevant antigens and enzymes for targeted drug delivery (Q27013843) (← links)
• Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines (Q33384571) (← links)
• Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma (Q33619401) (← links)
• Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint (Q34013882) (← links)
• Treatment options in hormone-refractory prostate cancer: current and future approaches (Q34481266) (← links)
• Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts (Q34482756) (← links)
• Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer (Q34722249) (← links)
• A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours (Q35034584) (← links)
• Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol (Q35125721) (← links)
• Development of a peptide-drug conjugate for prostate cancer therapy. (Q35184864) (← links)
• The Ron receptor promotes prostate tumor growth in the TRAMP mouse model. (Q35190869) (← links)
• Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer (Q35571704) (← links)
• Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia (Q35577352) (← links)
• Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer (Q35788601) (← links)
• A novel fully human antitumor immunoRNase resistant to the RNase inhibitor (Q36610794) (← links)
• Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer (Q37299843) (← links)
• Serially heterotransplanted human prostate tumours as an experimental model (Q37310963) (← links)
• Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells (Q37586081) (← links)
• Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients (Q38796138) (← links)
• The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells (Q38927764) (← links)
• 123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy (Q39523112) (← links)
• Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma (Q39543096) (← links)
• Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). (Q40809042) (← links)
• Tumor-associated antigens for specific immunotherapy of prostate cancer (Q41977894) (← links)
• Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines (Q42018419) (← links)
• Her-2/neu oncogene amplification in clinically localised prostate cancer (Q42252556) (← links)
• Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms (Q43199031) (← links)
• Immunotherapy for prostate cancer (Q80150393) (← links)
• [Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches] (Q80697262) (← links)
• Immunotherapy for prostate cancer (Q83186193) (← links)
• ErbB-2 signaling in advanced prostate cancer progression and potential therapy (Q91790579) (← links)